Peptide Therapeutics

Global Peptide Therapeutics Market to Reach US$56.3 Billion by 2030

The global market for Peptide Therapeutics estimated at US$43.7 Billion in the year 2024, is expected to reach US$56.3 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$29.9 Billion by the end of the analysis period. Growth in the Generic segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.5 Billion While China is Forecast to Grow at 7.4% CAGR

The Peptide Therapeutics market in the U.S. is estimated at US$11.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$12.4 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Peptide Therapeutics Market – Key Trends & Drivers Summarized

How Are Technological Advances Enhancing Peptide Therapeutics Development?

The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing. Furthermore, advances in delivery systems, such as nanoparticle encapsulation and peptide-drug conjugates, are improving the effectiveness of peptide-based treatments by enabling targeted delivery to specific tissues or cells. Technologies such as peptide stapling, which stabilizes the peptide structure, and the use of peptidomimetics, which mimic peptide activity while enhancing stability, are also contributing to the growth of peptide therapeutics. These innovations are enabling the development of peptides that can treat a wide range of conditions, from metabolic disorders to oncology and infectious diseases, with greater efficacy and fewer side effects.

Why Are Peptide Therapeutics Gaining Popularity in Modern Medicine?

Peptide therapeutics are gaining significant popularity in modern medicine due to their unique ability to interact with specific receptors and cellular targets, offering precision in treatment that is often unmatched by small molecules or traditional biologics. Peptides are known for their high specificity and low toxicity, which makes them particularly attractive in the treatment of chronic diseases such as cancer, cardiovascular diseases, and metabolic disorders. Peptide-based therapies, including GLP-1 agonists for diabetes and vasopressin receptor antagonists for heart failure, have shown remarkable efficacy, driving their adoption in clinical settings. Additionally, peptides are increasingly being explored for their role in immunotherapy, with peptide vaccines being developed to trigger immune responses against cancers and infectious diseases. The relatively simple and scalable manufacturing processes for peptides compared to larger biologics also make them a cost-effective option for drug development. As the demand for targeted and safer therapies grows, peptide therapeutics are becoming a key focus in the development pipelines of major pharmaceutical companies.

How Are Industry and Healthcare Trends Shaping the Peptide Therapeutics Market?

Industry and healthcare trends are playing a significant role in shaping the peptide therapeutics market, particularly with the rise of personalized medicine and targeted therapies. As the healthcare sector shifts toward individualized treatments, peptides are becoming integral due to their ability to target specific molecular pathways associated with disease progression. This is particularly true in oncology, where peptides are being used for targeted drug delivery and as agents in cancer immunotherapies. The growing prevalence of chronic diseases, especially diabetes and obesity, has also led to increased interest in peptide therapeutics, with drugs like GLP-1 analogs becoming standard treatments for these conditions. Furthermore, advancements in biotechnology are making it easier to modify peptides for improved stability, bioavailability, and delivery, which is expanding their therapeutic potential. The rise of biologics and the focus on reducing the side effects associated with conventional therapies are further accelerating the development of peptide-based drugs across multiple therapeutic areas.

What Factors Are Driving Growth in the Peptide Therapeutics Market?

The growth in the peptide therapeutics market is driven by several factors, including technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. One of the primary drivers is the expanding use of peptides in the treatment of conditions like cancer, metabolic disorders, and cardiovascular diseases, where their high specificity and low toxicity provide significant therapeutic advantages. Technological innovations in peptide stabilization and delivery are also propelling the market, making it possible to develop peptides that are more durable and effective in the body. Additionally, the rising focus on personalized medicine is increasing the demand for peptide-based treatments, as they can be tailored to target specific pathways involved in disease progression. The growing interest in immunotherapy, particularly for cancer and infectious diseases, is also contributing to market expansion, with peptide vaccines and conjugates playing a crucial role in this space. Furthermore, the relatively lower production costs associated with peptide therapeutics compared to larger biologics are encouraging pharmaceutical companies to invest more heavily in this area, further driving growth in the peptide therapeutics market.

SCOPE OF STUDY:

The report analyzes the Peptide Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Innovative, Generic); Synthesis Technology (Liquid Phase, Solid Phase, Hybrid Phase); Application (Metabolic, Cancer, Cardiovascular Disease, Anti-Infection, Respiratory, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 33 Featured) -

• AbbVie, Inc.
• Advanced Accelerator Applications SA
• Akashi Therapeutics, Inc.
• Amgen, Inc.
• Anthera Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bachem AG
• Bristol-Myers Squibb Company
• Cardiorentis AG
• Corden Pharma International GmbH
• Debiopharm Group
• Derma Sciences, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Hanmi Pharmaceutical Co., Ltd.
• Insmed, Inc.
• Ipsen Group
• Johnson & Johnson
• Lonza Group AG
• Mallinckrodt PLC
• Merck & Co., Inc.
• MolMed S.p.A.
• Novartis AG
• Novo Nordisk A/S
• Nymox Pharmaceutical Corporation
• PAR Pharmaceutical Companies, Inc.
• PeptiDream Inc.
• Pfizer, Inc.
• PolyPeptide Group
• Radius Health, Inc.
• Repligen Corporation
• Sanofi SA
• SciClone Pharmaceuticals Holding Limited.
• Shire PLC
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• The Medicines Company
• X-GEN Pharmaceuticals, Inc.
• Zealand Pharma A/S
• Zydus Cadila

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.